Lynparza Receives European Approval for Pancreatic Cancer

The European Commission has approved AstraZeneca and Merck’s Lynparza (olaparib) for treatment of adults with germline BRCA-mutated metastatic pancreatic cancer who have not progressed after 16 weeks of chemotherapy.

The approval was based on the results of a phase 3 clinical trial in which Lynparza increased the time patients lived without disease progression or death to 7.4 months compared to 3.8 months on placebo.

The FDA approved Lynparza for the same indication in December 2019.